Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Alzheime's Disease
11%
Alzheimer's Disease
11%
Cell Death Markers
11%
Central Nervous System
11%
Chronic Administration
11%
Cognitive Impairment
11%
Concussive
11%
Dose-dependent
11%
Dosing Regimen
11%
Drop Weight
11%
Exenatide
100%
Glucagon-like
11%
Immunohistochemical Evaluation
11%
Inflammatory Markers
11%
Injury Treatment
11%
Mild Traumatic Brain Injury (mTBI)
100%
Mouse Model
11%
Multiple Sclerosis
11%
Multiple System Atrophy
11%
Murine Model
100%
Neurodegenerative Disorders
11%
Neurological Disorders
11%
Neuronal Cell Death
11%
Neuroprotective Effect
22%
Neurotrophic Effect
22%
Parkinson's Disease
11%
Pharmacokinetics
100%
Pharmacological Treatment
11%
Plasma Parameters
11%
Repeated Administration
11%
Single post
11%
Spatial Deficit
11%
Steady-state Conditions
11%
Subcutaneous Injection
22%
Sustained Release
100%
Traumatic Brain Injury
33%
Visual Deficits
11%
Neuroscience
Alzheimer's Disease
11%
Blood Plasma
33%
Central Nervous System
11%
Cognitive Disorders
11%
Drug Therapy
11%
Exenatide
100%
Glucagon-Like Peptide-1
11%
Multiple Sclerosis
11%
Multiple System Atrophy
11%
Nervous System Disorder
11%
Neurodegenerative Disorder
11%
Neuronal Cell Death
11%
Neuroprotective Agent
22%
Neurotrauma
100%
Parkinson's Disease
11%
Pharmacokinetic
100%
Traumatic Brain Injury
100%
Pharmacology, Toxicology and Pharmaceutical Science
Alzheimer's Disease
11%
Cognitive Defect
11%
Diseases
11%
Exendin 4
100%
Glucagon-Like Peptide-1
11%
Mouse Model
11%
Multiple Sclerosis
11%
Neuroprotective Agent
22%
Parkinson's Disease
11%
Pharmacokinetics
100%
Preclinical Study
11%
Shy Drager Syndrome
11%
Subcutaneous Injection
22%
Sustained Release
100%
Traumatic Brain Injury
100%